Crohn's Disease
VIDEO: AI cannot replace GI physicians, but ‘with supervision’ may enhance IBD care
In a Healio video exclusive, Edward V. Loftus Jr., MD, acknowledged that although artificial intelligence has potential to radically change the way gastroenterologists practice medicine, “it’s not going to replace you.”
FDA gains steam in 2023: GI pipeline boasts numerous milestones, 2 crucial setbacks
The first half of 2023 has already seen landmark FDA decisions in the gastroenterology space, including multiple first-in-class therapies along with two costly rejections that highlight persistent gaps in the GI drug armory.
Crohn’s disease more prevalent among pediatric patients with hidradenitis suppurativa
Pediatric patients with hidradenitis suppurativa are more than four times more likely to have Crohn’s disease compared with those without hidradenitis suppurativa, according to a study.
AI shows promise in diagnosis, treatment of IBD, but limitations, concerns remain
Artificial intelligence has been used in various ways to benefit patients with inflammatory bowel disease, with one of the main applications being the prediction and diagnosis of disease.
‘High-tech, high-touch’ patient care key to improving chronic conditions like Crohn’s
The prospect of managing a lifelong disease can be daunting, and many patients with chronic conditions struggle with consistent health monitoring, treatment adherence and implementing the changes needed to manage their disease.
Motorized spiral enteroscopy bests single-balloon in deeper bowel evaluation for Crohn’s
Motorized spiral enteroscopy may have a technical advantage over single-balloon enteroscopy in reaching mid-small bowel lesions and examining a greater length of bowel in a shorter period of time in patients with suspected Crohn’s disease.
Immunomodulators heighten risk for high-grade cervical neoplasia, cancer in women with IBD
Cumulative exposure to immunomodulators increased the risk for high-grade cervical intraepithelial neoplasia and cervical cancer in women with inflammatory bowel disease, according to data from Alimentary Pharmacology & Therapeutics.
Digestive Disease Week roundup: Colorectal cancer data dominated; what else did you miss?
Digestive Disease Week 2023 in Chicago may have ended in early May, but Healio coverage has continued all month long. Wondering what you missed and what is coming next? Healio recaps the biggest meeting news making waves in the specialty.
More than 60% of Crohn’s patients sustained remission with subcutaneous biosimilar CT-P13
CHICAGO — Subcutaneous maintenance therapy with an infliximab biosimilar after IV induction resulted in sustained clinical remission and greater endoscopic response vs. placebo in patients with moderate to severe Crohn’s disease.
FDA approves Rinvoq as first oral therapy for moderate to severe Crohn’s disease
The FDA has approved AbbVie’s Rinvoq as a once-day pill intended for the treatment of adult patients with moderate to severe Crohn’s disease who are intolerant, or have had an inadequate response, to one or more TNF inhibitors.